Biopharmaceutical company ANI Pharmaceuticals Inc (Nasdaq:ANIP) announced on Tuesday the launch of Baclofen Oral Suspension, a generic alternative to Fleqsuvy.
Baclofen Oral Suspension is a treatment for spasticity from multiple sclerosis or spinal cord injuries and other spinal cord diseases. Fleqsuvy is marketed by Azurity Pharmaceuticals Inc.
Total US annual sales for Baclofen Oral Suspension amount to approximately USD39m, according to IQVIA data.
Hikma Pharmaceuticals extends KLOXXADO nasal spray shelf-life 8mg from 24 to 36 months
Sun Pharma's LEQSELVI 8mg tablets receive US FDA approval
Emmaus Life Sciences names new chief executive officer
Biocon seeking partner to test semaglutide generics in China
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
ANI Pharmaceuticals launches generic Baclofen Oral Suspension
Biocon Biologics enters five-year partnership with Sandoz Australia
Mallinckrodt names new directors
Rottendorf Pharma enhances operations with Rockwell Automation's FactoryTalk PharmaSuite MES
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)